Nebenwirkungen · Onivyde pegylated liposomal (previously Onivyde)
ONIVYDE pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-135466 · Präparat HOS-097714
ONIVYDE pegylated liposomal in combination with 5-fluorouracil and leucovorin: The following adverse reactions, related to the administration of ONIVYDE pegylated liposomal, were reported in 264 patients with metastatic adenocarcinoma of the pancreas treated after disease progression following gemcitabine-based therapy. The most common adverse reactions (incidence ≥ 20%) of ONIVYDE pegylated liposomal +5-FU/LV were: diarrhoea, nausea, vomiting, decreased appetite, neutropenia, fatigue, asthenia, anaemia, stomatitis and pyrexia. The most common serious adverse reactions (≥ 2%) of ONIVYDE pegylated liposomal therapy were diarrhoea, vomiting, febrile neutropenia, nausea, pyrexia, sepsis, dehydration, septic shock, pneumonia, acute renal failure, and thrombocytopenia. The rates of adverse reactions leading to permanent treatment discontinuation were 11% for the ONIVYDE pegylated liposomal +5-FU/LV arm. The most frequently reported adverse reactions leading to discontinuation were infection and diarrhoea for ONIVYDE pegylated liposomal +5-FU/LV arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-29T09:48:00Z · SHA-256 6fe241cd32f9f9d3c8592da7ea124a85ef29388269021487b0409971bc580040 · Passage 9d0ace3a09ccd0059b741eafd7e8b5bcbe71492631cef01eaab31908fc88540e · Zeichen 1681–2741 im Abschnitt